Ohio State Navbar

Sign In

Archives

August 2019 (9)
July 2019 (4)
June 2019 (3)
May 2019 (6)
April 2019 (7)
March 2019 (6)
February 2019 (2)
January 2019 (7)
December 2018 (1)
November 2018 (1)
August 2018 (1)
June 2018 (1)
May 2018 (1)
February 2018 (1)
December 2017 (1)
August 2017 (4)
July 2017 (4)
June 2017 (6)
May 2017 (1)
March 2017 (6)
January 2017 (1)
December 2016 (1)
November 2016 (3)
October 2016 (3)
September 2016 (1)
August 2016 (4)
July 2016 (5)
June 2016 (9)
May 2016 (8)
March 2016 (2)
February 2016 (4)
December 2015 (4)
November 2015 (3)
October 2015 (2)
September 2015 (4)
July 2015 (7)
June 2015 (3)
May 2015 (7)
April 2015 (3)
March 2015 (2)
February 2015 (2)
January 2015 (2)
December 2014 (3)
November 2014 (8)
October 2014 (7)
September 2014 (3)
August 2014 (7)
July 2014 (4)
June 2014 (3)
May 2014 (1)
April 2014 (3)
March 2014 (6)
February 2014 (4)
January 2014 (1)
December 2013 (6)
November 2013 (4)
October 2013 (1)
September 2013 (1)
August 2013 (9)
July 2013 (1)
June 2013 (9)
May 2013 (14)
April 2013 (13)
March 2013 (9)
February 2013 (8)
January 2013 (6)
December 2012 (7)
November 2012 (7)
October 2012 (9)
September 2012 (6)
August 2012 (12)
July 2012 (6)
June 2012 (8)
May 2012 (14)
April 2012 (7)
March 2012 (4)
February 2012 (11)
January 2012 (8)
December 2011 (5)
November 2011 (7)
October 2011 (9)
September 2011 (5)
August 2011 (3)
July 2011 (8)
June 2011 (1)
May 2011 (10)
April 2011 (4)
March 2011 (5)
February 2011 (9)
January 2011 (2)
December 2010 (2)
November 2010 (3)
September 2010 (4)
August 2010 (6)
July 2010 (6)
June 2010 (6)
May 2010 (1)
April 2010 (3)
February 2010 (3)
January 2010 (2)
December 2009 (3)
September 2009 (6)
August 2009 (1)
July 2009 (2)

Categories


RSS Feed College of Medicine News


Scientists ID New Metabolic Target to Prevent, Treat Heart Failure at Earliest Stage 

 

Scientists ID new metabolic target.pngResearchers with Ohio State's College of Medicine and Wexner Medical Center have identified a metabolic process in the heart that, if treated, could someday prevent or slow the progression of heart failure.

The American Heart Association journal Circulation has published the findings.

Before any physical signs or symptoms of heart failure are present, the first maladaptive changes occur in cardiac cell metabolism – how the heart fuels itself to pump blood through the body constantly.

"Our hearts burn fuel, much like combustion engines in cars. Instead of gasoline, our heart cells burn fats and a small amount of glucose," says Doug Lewandowski, director of Translational Research at Ohio State's Davis Heart and Lung Research Institute. "When our hearts become chronically stressed, they try to adapt, but some of those changes make things worse." 

For their research, Lewandowski's team examined both mouse models of heart failure and human heart tissue obtained from heart failure patients before and after heart assist devices were surgically implanted. They found that the amount of a reactive fat compound, called acyl-CoA, is nearly 60 percent lower in failing hearts compared to normal hearts. This disruption in the heart's normal metabolism creates toxic fats that impair the heart's ability to function and pump properly.

Then the team tested mice that overexpressed a gene for a protein called ACSL1, that's known to make acyl-CoA. When exposed to conditions that cause heart failure, the mice kept making normal amounts of acyl-CoA and the extent of heart failure was reduced and delayed. 

"By maintaining this fat compound, acyl-CoA, the hearts retained their ability to burn fat and generate energy. Importantly, overexpression of ACSL1 also reduced toxic fats, normalized cell function and reduced the progressive loss of function in the enlarged mouse hearts," said Lewandowski, who is also a professor of internal medicine at Ohio State's College of Medicine. 

When the team examined failing human hearts that had the help of a left ventricular assist device (LVAD), they found similar effects – the levels of acyl-CoA had restored to normal when the sick hearts didn't have to work beyond their capacity. 

"This tells us there's an important relationship between fat metabolism in the heart and the inability to pump well, and we need to learn more. We believe targeting the normalization of acyl-CoA through gene or drug therapy or, potentially, dietary protocols, is a new approach to explore," Lewandowski said. 

"Heart failure is the only form of heart disease that hasn't dropped in 35 years. As findings like these help identify the metabolic underpinnings of the disease, it gives hope for promising new therapies for patients," says Dr. K. Craig Kent, dean of the College of Medicine.  

Next, Lewandowski's team wants to explore how normalizing acyl-CoA helps reduce toxic fats and increase protective fats inside the heart. Soon, they hope to use advanced imaging to track fat metabolism and function in patients' hearts.

"We need to understand how we're manipulating the chemical reactions and what exactly is leading to the improvement. Then we can look at whether we can supply the heart with fats, supplements or medications that assist with creating acyl-CoA. Ultimately, it's about trying to prevent or slow the progression toward heart failure," Lewandowski said.

Funding from the National Institutes of Health helped to support this research. Additional scientists involved in the study include Andrew Carley and Matt Fasano from Ohio State, Dr. Joseph Goldenberg from the University of Illinois, Dr. Christian Schulze from the University of Jena and Columbia University Medical Center, and Dr. Ruiping Ji and Xiaokan Zhang from Columbia University Medical Center.

 

Posted on 27-Mar-19 by Jarvis, Blake
Tags: Patient Care, Research
 
Trackback Url  |  Link to this post | Bookmark this post with: